Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Current Deferred Revenue (2021 - 2025)

BioNexus Gene Lab's Current Deferred Revenue history spans 5 years, with the latest figure at $11264.0 for Q3 2025.

  • For Q3 2025, Current Deferred Revenue fell 50.67% year-over-year to $11264.0; the TTM value through Sep 2025 reached $11264.0, down 50.67%, while the annual FY2024 figure was $95879.0, N/A changed from the prior year.
  • Current Deferred Revenue for Q3 2025 was $11264.0 at BioNexus Gene Lab, down from $11348.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $95879.0 in Q4 2024 and bottomed at $107.0 in Q1 2022.
  • The 5-year median for Current Deferred Revenue is $11348.0 (2025), against an average of $23758.7.
  • The largest annual shift saw Current Deferred Revenue crashed 70.08% in 2022 before it soared 14219.63% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $77276.0 in 2021, then plummeted by 70.08% to $23123.0 in 2022, then plummeted by 64.46% to $8218.0 in 2023, then soared by 1066.7% to $95879.0 in 2024, then plummeted by 88.25% to $11264.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Current Deferred Revenue are $11264.0 (Q3 2025), $11348.0 (Q2 2025), and $21964.0 (Q1 2025).